Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The addition of phorbol esters to U937 leukemic cells stimulates the phosphorylation of
c-Jun
on serines 63 and 73. To isolate the
protein kinase
which stimulates this phosphorylation, we have used heparin-Sepharose chromatography followed by affinity chromatography over glutathione-Sepharose beads bound with a fusion protein of glutathione S-transferase and amino acids 5-89 of
c-Jun
(GST-c-Jun). Using this procedure we purify a 67-kDa protein which is capable of phosphorylating GST-
c-Jun
as well as the complete
c-Jun
protein. By making mutations in serines 63 and 73 and then creating a fusion protein with GST (GST-c-Jun mut), we demonstrate that this
protein kinase
specifically phosphorylates these sites in the
c-Jun
amino terminus. Treatment of purified
c-Jun
amino-terminal
protein kinase
(cJAT-PK) with phosphatase 2A inhibits its ability to phosphorylate GST-
c-Jun
. This inactivated enzyme can be reactivated by phosphorylation with protein kinase C (PKC), although PKC is not capable of phosphorylating the GST-
c-Jun
substrate. Because v-Jun cannot be phosphorylated in vivo, we compared the ability of cJAT-PK to bind to GST-v-Jun or GST-
c-Jun
mut. The cJAT-PK bound 50-fold better to GST-
c-Jun
mut than GST-v-Jun suggesting that the delta domain which is missing in v-Jun plays a role in binding the cJAT-PK. These results suggest that there is a
protein kinase
cascade mediated by protein phosphatases and PKC which regulates
c-Jun
phosphorylation.
...
PMID:Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. 132 19
The product of the c-jun proto-oncogene is the major component of the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-inducible
transcription factor AP-1
. Jun binds to the TPA-responsive elements (TREs) present in a large number of TPA-inducible genes, thereby regulating their expression in response to activation of protein kinase C. Previously we have shown that Jun/AP-1 can also activate cAMP-responsive elements (CREs), indicating the existence of cross-talk in signal transduction at the transcriptional level. Here we show that Jun/AP-1 is activated by the
cAMP-dependent protein kinase A
(
PKA
). In transient transfection experiments, TRE activation by Jun is strongly enhanced by co-transfection of the catalytic subunit of
PKA
or forskolin treatment, although not in all cell types studied. Jun activity can be significantly inhibited by co-transfection of the regulatory subunit of
PKA
. Furthermore, we show a cell-specific increase in AP-1 binding in response to forskolin treatment. However, since direct phosphorylation of Jun by
PKA
does not occur, we suggest an indirect activation mechanism.
...
PMID:Activation of Jun/AP-1 by protein kinase A. 133 36
Study of GSK-3 had an inauspicious beginning rooted in intermediary metabolism. However, owing to the fortuitous convergence of several disparate areas of biology, the enzyme now offers unique opportunities for study of the control of a variety cellular processes. While at first sight a role in transcriptional regulation appears unlikely for a protein first identified as acting on glycogen synthase, it is even more surprising that the same protein should be functionally interchangeable with a fruit fly homeotic gene. Such understandable scepticism, however, is based on teleological bias. Glycogen synthase is a critical enzyme regulating glucose storage. The
c-Jun
oncoprotein may have the potential to transform cells but this does not excuse it from similar mechanisms of control to glycogen synthase. Likewise, homeotic genes play a crucial role in setting up the body plan of an embryo but must also be subject to control. The main difference is that when such control is lost, the result is rather graphic. It is, therefore, only to be expected that regulatory protein kinases will surface in superficially quite unrelated areas and that many of their targets will be 'housekeeping' proteins. Perhaps the most difficult aspect of protein phosphorylation research is the linking of physiological substrates with particular protein kinases, hence reconstructing pathways. No matter how compelling in vitro data appear, there must be demonstration that the protein is targeted by the specific
protein kinase
in cells, an extremely difficult process. Most progress in this respect has been made using genetic analysis in lower organisms, especially yeast. Here another problem arises: demonstration of biochemical linkages underlying genetic interactions which requires function to be ascribed to genes identified by a gross effect. The challenge is to co-ordinate these two approaches, a strategy currently being employed to further unravel the biological role of GSK-3.
...
PMID:Glycogen synthase kinase-3: functions in oncogenesis and development. 133 7
Exposure of mammalian cells to DNA-damaging agents induces the ultraviolet (UV) response, involving
transcription factor AP-1
, composed of Jun and Fos proteins. We investigated the mechanism by which UV irradiation induces the c-jun gene. The earliest detectable step was activation of Src tyrosine kinases, followed by activation of Ha-Ras and
Raf-1
. The response to UV was blocked by tyrosine kinase inhibitors and dominant negative mutants of v-src, Ha-ras, and raf-1. This signaling cascade leads to increased phosphorylation of
c-Jun
on two serine residues that potentiate its activity. These results strongly suggest that the UV response is initiated at or near the plasma membrane rather than the nucleus. The response may be elicited by oxidative stress, because it is inhibited by elevation of intracellular glutathione. Using tyrosine kinase inhibitors, we demonstrate that the UV response has a protective function.
...
PMID:The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. 147 46
The recent finding that neurotransmitters and drugs that affect neurotransmission have important influences on gene expression suggests that drug-induced alterations in gene expression may underlie many long-term effects of addictive drugs, for example, dependence and drug-seeking behaviors. These long-term adaptive responses to opiate drugs have been particularly difficult to understand at a mechanistic level. Data presented here indicate that the gene encoding the opioid precursor proenkephalin is highly regulated by neural activity, second-messenger pathways, and
PKA
. These observations raise the possibility that drugs of abuse (e.g., opiates acting through opiate receptors) may act at the genetic level to modulate the expression of endogenous opiates and that these effects may underlie one component of the brain's long-term adaptive response to exogenous opiates. The transgenic animals described above can be used to investigate opiate drug-induced changes in proenkephalin gene expression, allowing rapid analysis of changes in proenkephalin gene expression in highly restricted populations of neurons in a fashion previously impossible. In addition, by analyzing the effects of specific enhancer mutations on tissue-specific and transsynaptic regulation of proenkephalin expression, transgenic models will permit mechanistic investigations within the intact nervous system that cannot otherwise be undertaken. Investigation of mechanisms underlying this process requires the analysis of intracellular signaling pathways, responsive DNA regulatory elements, and the transcription factors transducing synaptic signals into gene regulation. In the studies described herein, we demonstrate that AP-1 complexes consisting of different Jun proteins differentially regulate proenkephalin transcription at the CRE-2 element.
c-Jun
constitutively activates proenkephalin transcription, whereas JunD activates in a fashion completely dependent on the activation of second-messenger pathways and the cAMP-dependent
PKA
. JunB alone has no effect on proenkephalin gene expression, yet this molecule effectively blocks activation mediated by JunD and, hence, may act as a repressor. These data are consistent with a model (figure 4) in which preexisting JunD mediates the rapid cAMP-dependent activation of the proenkephalin enhancer, whereas IEGs such as JunB or c-Fos mediate the protein synthesis-dependent inactivation. Because
c-Jun
activates proenkephalin transcription constitutively, induction of
c-Jun
may lead to a further and prolonged activation of proenkephalin gene expression. Hence, the ratio of
c-Jun
to JunB induction may determine whether proenkephalin is repressed or further activated.
...
PMID:Regulation of opioid gene expression: a model to understand neural plasticity. 149 20
In conclusion, a multigene family (ERK) encoding protein kinases that have the capacity to convert tyrosine kinase signals to serine/threonine phosphorylation signals has been identified in animal and yeast cells. Protein kinases from this family have been shown to be phosphorylated on tyrosine and threonine in response to mitogens, as well as to have the capacity to autophosphorylate on these amino acid residues. In contrast, they apparently phosphorylate exogenous substrates on serine and/or threonine. Studies with cultured cells, Xenopus, and sea star oocytes have furthered our understanding of possible functions of Erks in vivo. These enzymes respond immediately to extracellular signals and are involved in G0-G1 transition (cultured cells), as well as in the M phase of oocyte maturation (Xenopus and sea star oocytes). Their usage of MAPs as substrates in vivo suggests a possible role of Erks in microtubule reorganization. ERK-encoded protein kinases use
c-Jun
, EGF receptor, and
Raf-1
as potential substrates and can also reactivate dephosphorylated S6 kinase in vitro. Taken together, these data suggest that these enzymes play an important role in relaying the mitogenic signal by phosphorylating down-stream kinases and specific transcriptional factors, as well as having possible feedback function in the process of signal transduction. The results from the study of the yeast enzymes are pertinent to Erk activation in cells with nonmitogenic responses described above. In such cases, Erk protein kinases may act directly or indirectly on cyclins to arrest division and permit differentiation. The pathways influenced by ERK-like gene products in animal and yeast cells suggest that, depending on the downstream targets of substrates, transcriptional changes in a particular cell may occur to drive the cell cycle or, alternatively, withdrawal from the cell cycle may lead to specific differentiation events.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Erks: their fifteen minutes has arrived. 150 18
c-Jun
, a major component of the inducible
transcription factor AP-1
, is a phosphoprotein. In nonstimulated fibroblasts and epithelial cells,
c-Jun
is phosphorylated on a cluster of two to three sites abutting its DNA-binding domain. Phosphorylation of these sites inhibits DNA binding, and their dephosphorylation correlates with increased AP-1 activity. We show that two of these sites, Thr-231 and Ser-249, are phosphorylated by
casein kinase II
(
CKII
). Substitution of the third site, Ser-243, by Phe interferes with phosphorylation of the inhibitory sites in vivo and by purified
CKII
in vitro. Microinjection into living cells of synthetic peptides that are specific competitive substrates or inhibitors of
CKII
results in induction of AP-1 activity and
c-Jun
expression. Microinjection of
CKII
suppresses induction of AP-1 by either phorbol ester or an inhibitory peptide. These results suggest that one of the roles of
CKII
, a major nuclear protein kinase with no known functions, is to attenuate AP-1 activity through phosphorylation of
c-Jun
.
...
PMID:Casein kinase II is a negative regulator of c-Jun DNA binding and AP-1 activity. 142 36
c-Jun
and its oncogenic counterpart v-Jun are completely conserved within the region from Ser-63 to Ser-73; these serines are sites for phorbol ester-inducible
c-Jun
phosphorylation. Using a U937 human leukemic cell line stably expressing v-Jun, we have demonstrated that phorbol esters stimulate the in vivo phosphorylation of
c-Jun
but not v-Jun. We developed an in vitro
protein kinase
assay to characterize the
c-Jun
protein kinase
and to examine the determinants underlying this differential phosphorylation. Fusion proteins between glutathione S-transferase and the N terminus of
c-Jun
, v-Jun, or several
c-Jun
mutants were used as substrates. A
c-Jun
kinase activity was affinity-purified 5000-fold by using glutathione S-transferase-
c-Jun
-glutathione-Sepharose beads and was found to phosphorylate the N terminus of
c-Jun
but not v-Jun or
c-Jun
containing a 27-amino acid N-terminal deletion found in v-Jun. These effects were also observed in vivo as phorbol 12-myristate 13-acetate did not induce the phosphorylation of v-Jun or the
c-Jun
deletion mutant in U937 cell lines stably expressing these proteins. These findings indicate that the delta domain of
c-Jun
(amino acids 34-60), which is deleted in v-Jun, plays a critical role in regulating N-terminal
c-Jun
phosphorylation.
...
PMID:Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: regulation by the N-terminal delta domain. 160 42
In resting cells,
c-Jun
is phosphorylated on five sites. Three of these sites reside next to its DNA binding domain and negatively regulate DNA binding. In response to expression of oncogenic Ha-Ras, phosphorylation of these sites decreases, while phosphorylation of two other sites within
c-Jun
's activation domain is greatly enhanced. Phosphorylation of these residues, serines 63 and 73, stimulates the transactivation function of
c-Jun
and is required for oncogenic cooperation with Ha-Ras. We now show that the same changes in
c-Jun
phosphorylation are elicited by a variety of transforming oncoproteins with distinct biochemical activities. These oncoproteins, v-Sis, v-Src, Ha-Ras, and
Raf-1
, participate in a signal transduction pathway that leads to increased phosphorylation of serines 63 and 73 on
c-Jun
. While oncogenic Ha-Ras is a constitutive stimulator of
c-Jun
activity and phosphorylation, the normal c-Ha-Ras protein is a serum-dependent modulator of
c-Jun
's activity.
c-Jun
is therefore a downstream target for a phosphorylation cascade involved in cell proliferation and transformation.
...
PMID:Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73. 163 Apr 58
The product of the junB gene, a gene homologous to the proto-oncogene c-jun, is a component of
transcription factor AP-1
. JunB expression is modulated by a wide variety of extracellular stimuli, such as serum, growth factors, phorbol esters (TPA) and activators of
protein kinase A
(
PKA
). In order to study the molecular basis of this complex regulation, we have cloned the mouse junB gene from a genomic testis library, and characterized the junB promoter. Here we show that the junB promoter is activated by serum, TPA, and activated
PKA
. Sequences located between -91 and -44 are necessary for induction. These sequences contain a CAAT box, a G-C rich region and a previously undescribed inverted repeat (IR). The IR element can mediate induction by TPA and
PKA
when coupled to a heterologous promoter, and specifically binds a protein of 110 kD.
...
PMID:Activation of junB by PKC and PKA signal transduction through a novel cis-acting element. 170 23
1
2
3
4
5
6
7
8
9
10
Next >>